Vera Therapeutics

VERA

Market cap $2.16B

An analyst expressed his very bullish view on the biotech in a new research note. He reiterated his equivalent of a buy recommendation, and his lofty price target.

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R.

BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025.

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p

BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 79,050 shares of Class A common stock and restricted stock units (RSUs) underlying 39,915 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Vera Therapeutics, Inc. ( VERA ) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy November 6, 2025 4:30 PM EST Company Participants Marshall Fordyce - Founder, President, CEO & Director Matt Skelton - Executive Vice President of Commercial Robert Brenner - Chief Medical Officer Conference Call Participants Richard Lafayette Anupam Rama - JPMorgan Chase & Co, Research Division Jonathan Barratt Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Ritu Baral - TD Cowen, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Farzin Haque - Jefferies LLC, Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Dina Ramadane - BofA Securities, Research Division Sadia Rahman - Wells Fargo Securities, LLC, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Vera Therapeutics Investor Call and Webcast.

BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy (IgAN) were presented as a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2025 and simultaneously published in The New England Journal of Medicine (NEJM).

ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025 Biologics License Application (BLA) submission through the Accelerated Approval Program for atacicept for the treatment of IgAN to U.S. FDA expected in Q4; potential U.S. commercial launch of atacicept in 2026 Actively enrolling patients in the PIONEER, atacicept monthly dose range finding, and ORIGIN Extend studies BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the third quarter ended September 30, 2025.

BRISBANE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host an investor call and webcast at 4:30 PM ET on Thursday, November 6, 2025 to review the data from the ORIGIN Phase 3 clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) presented at the morning plenary session at the American Society of Nephrology (ASN) Kidney Week 2025.